All In Biotech

NDA 022252 · Bayer Hlthcare

Natazia

Dienogest, Estradiol Valerate · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Jun 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

May 6, 2010

Approved uses

3

Original approval plus efficacy supplements

Registered trials

59

22 Phase 3, 3 recruiting

FAERS reports

322

63 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke. [See Contraindications ( 4 ).] WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. • Women over 35 years old who smoke should not use Natazia. ( 4 ) • Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. ( 4 )

What it is approved for

From the label in effect Jun 26, 2024.

• Natazia is a combination of dienogest , a progestin, and estradiol valerate, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. ( 1 ) • The efficacy of Natazia in females of reproductive potential with a body mass index (BMI) of >30 kg/m 2 has not been evaluated. ( 1 , 8.8 ) • Treatment of heavy menstrual bleeding in females of reproductive potential without organic pathology who choose to use an oral contraceptive as their method of contraception. ( 1.2 ) 1.1 Oral Contraception Natazia ® is indicated for use by women to prevent pregnancy. The efficacy of Natazia in women with a body mass index (BMI) of > 30 kg/m 2 has not been evaluated. 1.2 Heavy Menstrual Bleeding Natazia is also indicated for the treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception [see Clinical Studies ( 14.2 )].

Mechanism: COCs lower the risk of becoming pregnant primarily by suppressing ovulation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • NATAZIA · DIENOGEST N/A,2MG,3MG,N/A,N/A; ESTRADIOL VALERATE 3MG,2MG,2MG,1MG,N/A · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dienogest" as an intervention, any sponsor and status, largest first.

All 59 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • metrorrhagia35
  • drug dose omission34
  • headache18
  • vaginal haemorrhage15
  • off label use14
  • menstruation delayed12
  • pregnancy on oral contraceptive12
  • nausea11
  • product use issue11
  • amenorrhoea10
  • product use in unapproved indication10
  • inappropriate schedule of drug administration9

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201012
201142
201243
201340
201426
201532
201622
201710
201816
201918
202013
20218
202210
20236
20245
20257
202612

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Natazia (Estradiol Valerate/Dienogest)

2024 spending

$99K

Beneficiaries

50

219 claims

Per beneficiary

$1,989

$8.79 per unit

View as table
YearSpending
2020$106,854
2021$108,158
2022$124,311
2023$121,123
2024$99,448

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 193 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.